Abstract: A control device includes an input interface to receive input information from an input device, an output interface to output output information to an output device, a sampler that generates a request identifier uniquely identifying the input information and sampling data in which the input information and the request identifier are associated with each other and stores the sampling data into a storage, and a controller that processes the input information associated with the request identifier as a request, generates process state information about a process, and causes the output interface to output a result of the process as the output information. The sampler further associates at least one of the process state information or the output information with the sampling data and stores the sampling data into the storage.

Abstract: A control device includes an input interface to receive input information from an input device, an output interface to output output information to an output device, a sampler that generates a request identifier uniquely identifying the input information and sampling data in which the input information and the request identifier are associated with each other and stores the sampling data into a storage, and a controller that processes the input information associated with the request identifier as a request, generates process state information about a process, and causes the output interface to output a result of the process as the output information. The sampler further associates at least one of the process state information or the output information with the sampling data and stores the sampling data into the storage.

Abstract: An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is —CH2— or —CO—; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R1 is a hydrogen atom or an aralkyl group; R2 is an alkyl group or an aralkyl group, etc.; R3 is a hydrogen atom or an alkyl group, etc.; R4 is a hydrogen atom or an alkyl group; R5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R6 is a hydrogen atom or an alkyl group; R7 is a hydrogen atom, etc.; R8 is a hydrogen atom, or an alkyl group, etc.; and E is —NHCO-G-COR12, etc. (wherein G is a single bond or an alkylene group, and R12 is a hydroxy group or an alkoxy group)].

Abstract: A dipeptidyl peptidase IV inhibitor which is satisfactory in respect of activity, stability and safety and has an excellent action as a pharmaceutical agent. A compound represented by the following general formula or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each represents hydrogen, an optionally substituted C1-6 alkyl group, or —COOR5 whereupon R5 represents hydrogen or an optionally substituted C1-6 alkyl group, or R1, R2, and a carbon atom together represent a 3- to 6-membered cycloalkyl group, R3 represents hydrogen or an optionally substituted C6-10 aryl group, R4represents a hydrogen or a cyano group, D represents —CONR6-, —CO— or —NR6CO—, R6 represents hydrogen or an optionally substituted C1-6 alkyl group, E represents —(CH2)m— whereupon m is 1 to 3, —CH2OCH2—, or —SCH2—, n is 0 to 3, and A represents an optionally substituted bicyclic heterocyclic group or bicyclic hydrocarbon group.

Abstract: An optical communication system is formed by connecting a base station to user stations. Each user station has a transmitting section for upstream communication. The base station has a light source which supplies transmission light used for upstream communication.

Abstract: A dipeptidyl peptidase IV inhibitor which is satisfactory in respect of activity, stability and safety and has an excellent action as a pharmaceutical agent. A compound represented by the following general formula or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each represents hydrogen, an optionally substituted C1-6 alkyl group, or —COOR5 whereupon R5 represents hydrogen or an optionally substituted C1-6 alkyl group, or R1, R2, and a carbon atom together represent a 3- to 6-membered cycloalkyl group, R3 represents hydrogen or an optionally substituted C6-10 aryl group, R4 represents a hydrogen or a cyano group, D represents —CONR6—, —CO— or —NR6CO—, R6 represents hydrogen or an optionally substituted C1-6 alkyl group, E represents —(CH2)m— whereupon m is 1 to 3, —CH2OCH2—, or —SCH2—, n is 0 to 3, and A represents an optionally substituted bicyclic heterocyclic group or bicyclic hydrocarbon group.

Abstract: An optical communication system is formed by connecting a base station to user stations. Each user station has a transmitting section for upstream communication. The base station has a light source which supplies transmission light used for upstream communication.